Validation study of the Vitiligo Extent Score-plus - 19/04/18
Doi : 10.1016/j.jaad.2017.11.032
Nanja van Geel, MD, PhD a, ⁎ 
, Albert Wolkerstorfer, MD, PhD b, Janny E. Lommerts, MD b, Khaled Ezzedine, MD, PhD c, Viktoria Eleftheriadou, MD, PhD d, Iltefat Hamzavi, MD e, John Harris, MD, PhD f, Mauro Picardo, MD g, Alain Taieb, MD, PhD h, Cecilia A.C. Prinsen, MD, PhD i, Marcel Bekkenk, MD, PhD b, Reinhart Speeckaert, MD, PhD a
, Albert Wolkerstorfer, MD, PhD b, Janny E. Lommerts, MD b, Khaled Ezzedine, MD, PhD c, Viktoria Eleftheriadou, MD, PhD d, Iltefat Hamzavi, MD e, John Harris, MD, PhD f, Mauro Picardo, MD g, Alain Taieb, MD, PhD h, Cecilia A.C. Prinsen, MD, PhD i, Marcel Bekkenk, MD, PhD b, Reinhart Speeckaert, MD, PhD a a Department of Dermatology, Ghent University Hospital, Ghent, Belgium
b Department of Dermatology, University of Amsterdam and Netherlands Institute for Pigment Disorders, Amsterdam, The Netherlands
c Epidémiologie en Dermatologie et Evaluation des Thérapeutiques, Université Paris-Est, Service de Dermatologie, Hôpital Henri Mondor, Paris, France
d Centre of Evidence Based Dermatology, University of Nottingham, Nottingham, United Kingdom
e Department of Dermatology, Henry Ford Hospital, Detroit, Michigan
f Department of Medicine, Division of Dermatology, University of Massachusetts Medical School, Worcester, Massachusetts
g San Gallicano Dermatology Institute, Via Elio Chianesi, Rome, Italy
h National Reference Center for rare skin diseases, Hôpital St-André, University Hospital Center of Bordeaux, Bordeaux, France
i VU University Medical Center, Department of Epidemiology and Biostatistics, Amsterdam Public Health Research Institute, Amsterdam, The Netherlands
∗Reprint requests: Nanja van Geel, MD, PhD, Department of Dermatology, Ghent University Hospital, Corneel Heymanslaan 10, Ghent 9000, BelgiumDepartment of DermatologyGhent University HospitalCorneel Heymanslaan 10Ghent9000Belgium
| Funding sources: Supported by a European Academy of Dermatology and Venereology grant (EADV project proposal reference No. 2015-030) and Leo Foundation grant (Leo Foundation project reference No. LF16092). The research activities of the principle investigator (Dr van Geel) are supported by the Scientific Research Foundation-Flanders (FWO Senior Clinical Investigator 1831512N) and those of Dr Speeckaert are supported by a postdoctoral research grant (01P12914) from the Ghent University Special Research Fund. |
|
| Conflicts of interest: Drs van Geel, Speeckaert, Wolkerstorfer, Bekkenk, Lommerts, Ezzedine, and Prinsen were involved in the development stage of the VESplus and/or VES. |
|
| Presented at the Vitiligo International Symposium in Rome, Italy, on December 2, 2016; the Global Vitiligo Foundation 2017 Annual Abstract Session before the American Academy of Dermatology Conference in Orlando, FL, on March 2, 2017; the Vitiligo Global Issues Consensus Conference before the 2017 International Pigment Cell Conference conference in Denver, CO, on August 25, 2017; and the 26th European Academy of Dermatology Congress in Geneva, Switzerland, on September 14, 2017. |
© 2018
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 78 - N° 5
P. 1013-1015 - mai 2018 Retour au numéro
Article précédent
- An exploratory open-label, investigator-initiated study to evaluate the efficacy and safety of combination sonidegib and buparlisib for advanced basal cell carcinomas
- Duy Cong Tran, Ann Moffat, Richard Brotherton, Alana Pague, Gefei Alex Zhu, Anne Lynn S. Chang
- Lack of correlation of the patient-derived Vitiligo Disease Activity Index with the clinician-derived Vitiligo Area Scoring Index
- Jennifer Coias, Linda S. Hynan, Amit G. Pandya
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?